Drug Profile
Research programme: B-cell malignancy therapies - Zalicus
Alternative Names: CRx-501Latest Information Update: 28 Jul 2016
Price :
$50
*
At a glance
- Originator CombinatoRx
- Developer EPIRUS Biopharmaceuticals
- Class
- Mechanism of Action Adenosine A2A receptor agonists; Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued B-cell lymphoma; Multiple myeloma
Most Recent Events
- 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
- 17 Jul 2014 No development reported - Preclinical for B-cell lymphoma in USA (Parenteral)
- 17 Jul 2014 No development reported - Preclinical for Multiple myeloma in USA (Parenteral)